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Objective: Brazilian legislation has recently suggested the use of the qualitative hemolysin
test instead of isohemagglutinin titers as prophylaxis for acute hemolysis related to
plasma-incompatible platelet transfusions. The efﬁcacy of this test in preventing hemolytic
reactions has never been evaluated while isohemagglutinin titers have been extensively
studied. The main objective of this study was to evaluate the correlation between the results
of  these two tests. The impact of each type of prophylaxis on the platelet inventory man-
agement and the ability of the qualitative hemolysin test to prevent red cell sensitization
after the transfusion of incompatible units were also studied.
Methods: A total of 246 donor blood samples were evaluated using both isohemagglutinin
titers and the qualitative hemolysin test, and the results were statistically compared. Subse-
quently, 600 platelet units were tested using the hemolysin assay and the percentage of units
unsuitable for transfusion was compared to historical data using isohemagglutinin titers
(cut-off: 100). Moreover, ten patients who received units with minor ABO incompatibilities
that  were negative for hemolysis according to the qualitative hemolysin test were evaluated
regarding the development of hemolysis and red cell sensitization (anti-A or anti-B).
Results: Isohemagglutinin titration and the results of qualitative hemolysin test did not cor-
relate. The routine implementation of the qualitative hemolysin test signiﬁcantly increased
the percentage of platelet units found unsuitable for transfusions (15–65%; p-value <0.001).
Furthermore the qualitative hemolysin test did not prevent red blood cell sensitization in a
small exploratory analysis.
Conclusion: Qualitative hemolysin test results do not correlate to those of isohemagglutinin
titers and its implementation as the prophylaxis of choice for hemolysis associated with
plasma-incompatible platelet transfusions lacks clinical support of safety and signiﬁcantlyaffects platelet inventory 
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Introduction
The transfusion of non-ABO identical platelets may be asso-
ciated with acute hemolysis, fever, recipient inﬂammation
and a decreased response in the post-transfusion platelet
count.1 There are two  types of ABO incompatibilities: (1) major,
in which the recipient plasma is not compatible with the
transfused platelets, a situation associated with a suboptimal
response to the transfused product and (2) minor, in which the
recipient is exposed to ABO-incompatible plasma when there
is the risk of acute hemolytic transfusion reactions.2 In the
routine of any blood bank, the transfusion of platelets with
minor ABO incompatibilities is not rare due to the shortage of
platelet concentrates and the number of emergency platelet
requests when no ABO typing is available.
The incidence of acute hemolysis due to plasma-
incompatible platelet transfusions is low (approximately 50 in
every 1,000,000 incompatible transfusions),3 but the severity of
the event justiﬁes the application of prophylactic policies. The
American Association of Blood Banks (AABB) standards state
that the transfusion service shall have a policy concerning the
transfusion of components containing signiﬁcant amounts of
incompatible ABO antibodies.4 Titration of donor isohemag-
glutinins (anti-A and/or anti-B) followed by the transfusion
of incompatible products with titers below 100 is the most
studied prophylactic method reported in the literature.1,5 In
spite of the discussion over the safest isohemagglutinin titer,
this strategy has already been evaluated in large studies which
demonstrated its efﬁcacy in preventing acute hemolysis after
plasma-incompatible platelet transfusions.5–7
Recently, the Brazilian legislation has suggested the use of
the qualitative hemolysin test (QHT) instead of isohemagglu-
tinin titers (IT) as prophylaxis for acute hemolysis secondary
to plasma-incompatible platelet transfusions.8 The rationale
is to identify, within the incompatible sera, the presence of
antibodies with the ability of causing red blood cell (RBC) lysis,
thereby reducing the risk to blood recipients. The proposed
test has three possible results: ‘absence of hemolysis’, ‘par-
tial hemolysis’ and ‘total hemolysis’, with the ‘partial’ and
‘total’ hemolysis categories precluding transfusion. In spite of
its biological plausibility, the efﬁcacy of the QHT in preven-
ting hemolytic reactions after the transfusion of products with
minor ABO incompatibilities has never been evaluated in the
literature, raising concerns about the safety of its use.
Thus, the main objective of this study was to evaluate the
correlation between isohemagglutinin titers (gold-standard
prophylaxis) and the qualitative hemolysin test (suggested
prophylaxis). A secondary objective was to evaluate the impact
of each type of prophylaxis on platelet inventory management
and the presence of RBC sensitization by anti-A or anti-B anti-
bodies after plasma-incompatible platelet transfusions tested
negative for hemolysis (absence of hemolysis) by QHT.
MethodsStudy  design
This study was approved by the local Ethics Committee (Fac-
uldade de Medicina da Universidade de São Paulo #797.385). In 2 0 1 5;3  7(4):217–222
the ﬁrst stage, samples obtained from type O platelet donors
between January 9, 2014 and September 30, 2014 were eval-
uated using both the QHT and IT techniques. The QHT  was
performed in the immunohematology laboratory and the IT
was measured in the laboratory responsible for the distribu-
tion of platelet units. All donor samples were collected using
tubes without anti-coagulant and the QHT was performed
within 6 h of collection. The IT was performed directly from
the sera of platelet units. The results of QHT and IT were sta-
tistically compared using the Kruskal–Wallis test, Chi-square
test and logistic regression. Statistical analysis was performed
using the SPSS software (18th version) and a p-value less than
0.05 was considered signiﬁcant.
In the second stage of the study, an exploratory sample of
ten patients who received minor ABO-incompatible platelet
transfusions were evaluated regarding the direct antiglobulin
test (DAT), lactate dehydrogenase (LDH) and indirect biliru-
bin (IB) before and 1 h after the transfusion of platelet units
with negative results for hemolysis using the QHT test. In
the speciﬁc case of type O platelet units, only those pre-
senting absence of hemolysis with both type A1 and B RBCs
were included, irrespective of the recipients’ ABO type. All
the patients were transfused in a day-hospital regimen and
patients were observed for 1 h after the end of transfusion
for signs and symptoms of acute hemolysis: fever, dark urine,
hypotension and lumbar pain. Increases of 15% in LDH or IB
levels were considered evidence of hemolysis as this level
exceeds the analytical variability of the laboratory for both
tests.
The QHT was also performed in samples obtained from all
platelet apheresis donors between June and September 2014.
The percentage of units classiﬁed as unsuitable for transfu-
sion using the QHT (partial or total hemolysis) was compared
to historical data of units classiﬁed as unsuitable for transfu-
sion using IT with a cut-off of 100 (Olympus PK 7200). These
percentages were compared using the Chi-square test.
Acid  elution
Acid elution was performed in cases of positive DAT using
the DiaCidel® kit, according to manufacturer’s instructions
(Biorad®). Brieﬂy, the RBCs of recipients were washed ten times
with 0.9% saline solution and 1 mL  of the elution solution was
added to 1 mL  of washed RBC. The mixture was centrifuged
and buffer solution was added to the supernatant until it
became blue. The eluate was then tested with commercial
type A1 and B RBCs.
Isohemagglutinin  titration  technique
Anti-A and anti-B titration was performed in tubes accord-
ing to the AABB Technical Manual (18th version).9 Brieﬂy, the
serum of platelet units was sequentially diluted in sterile
saline solution from 1:1 until 1:2048 giving a ﬁnal volume in
each case of 100 L. The titers were added to properly identi-
ﬁed tubes containing 50 L of type A1 or B RBCs (Biorad®). After
15 min  of incubation at room temperature the tubes were cen-
trifuged at 3000 rpm for 20 s. The results were interpreted by
macroscopically observing hemagglutination and classiﬁed as
previously described.9 The platelet isohemagglutinin titer was
er. 2 0 1 5;3  7(4):217–222 219
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Figure 1 – Comparison of the median value of
isohemagglutinin titers (IT) presented by the groups with
different results in the qualitative hemolysin test (QHT).rev bras hematol hemot
epresented by the highest titer at which 1+ hemagglutination
as observed.
ualitative  hemolysin  test
HT was performed according to a previously published
echnique.10 As Brazilian law suggests performing the QHT
fter 15 min  of incubation at 37 ◦C, this was the ﬁrst method
sed in the current study. However, a 30% rate of inter-
bserver disagreement was detected. In the literature, the
quivalent QHT technique uses 45 min  of incubation at room
emperature. This was also employed in this study with-
ut any inter-observer disagreement. Brieﬂy, fresh type A1
nd B non-commercial RBCs were used to prepare 3% sus-
ensions for the tests. Fresh donor sera (100 L) were added
o tubes containing 50 L of speciﬁc RBC suspensions (type
1 and/or B). After 45 min-incubation at room temperature,
he presence or absence of hemolysis was macroscopically
bserved in the tubes. The test was considered negative in
he absence of hemolysis. If there was hemolysis, the test was
onsidered positive and classiﬁed as partial or total hemol-
sis. Macroscopic evaluation of all samples was performed
y one technician and conﬁrmed by a second to avoid any
nterpretation bias.
esults
orrelation  between  qualitative  hemolysin  test  and
sohemagglutinin  titration  results
wo hundred and forty-six donors were evaluated using both
he QHL and IT techniques. On using the QHT, 61.38% of donors
id not exhibit hemolysis and 38.62% exhibited either partial
17.07%) or total hemolysis (21.54%). By IT, 85.8% and 67.1% of
latelet units were classiﬁed as low-titer considering cut-offs
f 1:128 and 1:64, respectively (Table 1).
The median value of IT did not statistically differ between
he groups with different QHT results, either when they
Table 1 – Isohemagglutinin titers and the qualitative
hemolysin test results of the study sample.a
Qualitative hemolysin test Frequency Percent
Absence of hemolysis 151 61.38
Partial hemolysis 42 17.07
Total hemolysis 53 21.54
Presence of hemolysis 151 61.38
Absence of hemolysis 95 38.62
Isohemagglutinin titers (cut-off) Frequency Percent
<1:128 211 85.8
≥1:128 35 14.2
<1:64 165 67.1
≥1:64 81 32.9
a The isohemagglutinin titer test was performed in platelet units
in one speciﬁc blood bank laboratory responsible for their dis-
tribution. Thus, the frequencies exhibited here are not the same
as those of the overall platelet units of the institution, especially
regarding the qualitative hemolysin test, due to necessity of pro-
viding units negative for hemolysis to patients.
Groups did not statistically differ in terms of IT, in spite of
their classiﬁcation as absence of hemolysis, partial
hemolysis and total hemolysis (p-value = 0.919) (A) or
absence of hemolysis and presence of hemolysis
(p-value = 0.733) (B). In fact, the median IT was 32 and the
interquartile range was 48 for all analyzed groups.were classiﬁed as absent, partial and total hemolysis (p-
value = 0.919) or when they were classiﬁed as absence and
presence of hemolysis (p-value = 0.733) (Figure 1). In fact, the
median value of IT was 32 and the interquartile range was 48
in all analyzed groups.
Neither titers above 64 nor titers above 128 were correlated
to the risk of hemolysis according to the QHT (p-value = 0.454
and 0.677, respectively) (Table 2). Logistic regression analy-
sis demonstrated that the IT was unable to predict the QHT
results (p-value = 0.702).
Evaluation  of  the  efﬁcacy  of  the  qualitative  hemolysin  test
in preventing  red  cell  sensitizationTen patients were evaluated regarding the presence of
anti-A and anti-B within their RBC membranes after
220  rev bras hematol hemoter. 2 0 1 5;3  7(4):217–222
Table 2 – Comparison between isohemagglutinin titers (IT) and qualitative hemolysin test results using the Chi-square
test.
Cut-off Qualitative hemolysin test Total p-value
Presence of hemolysis Absence of hemolysis
IT <1:128 127 84 211 0.677
≥1:128 24 11 35
Total 151 95 246
IT <1:64 103 62 165 0.454
≥1:64 48 33 81
Total 151 
plasma-incompatible platelet transfusions with negative test
results for hemolysis using the QHT. All the patients received
less than 600 mL  of incompatible plasma and there were
no increases in the levels of DHL or IB in any patient after
the transfusion. One patient developed a novel positive DAT
after the transfusion and the eluate analysis conﬁrmed anti-B
speciﬁcity (IT 1:128) (Table 3). No signs or symptoms of trans-
fusion reactions were detected.
Impact  of  the  implementation  of  the  qualitative  hemolysin
test on  the  blood  bank  routine
Six hundred platelet units (apheresis only) were studied and
the percentage considered as unsuitable for transfusion due to
minor ABO incompatibility was calculated. The percentage of
group O platelet apheresis considered as unsuitable for trans-
fusion using the QHT was 65% and, based on historical data,
the percentage of group O platelet units considered as unsuit-
able for transfusion using IT (cut-off of 100) was 15% (p-value
<0.01). This would signiﬁcantly affect platelet supply in blood
banks in the case of minor ABO incompatibility. As the test
could not be automatized, QHT was performed manually and
only using the sera of apheresis donors.
Table 3 – Overall characterization of the patients including the 
Case Transfused platelet units 
Type of
transfused
platelet
Transfused
volume (mL)
%  of incompatible
platelet units (pool)
ABO/
RhD
1 Apheresis 250 O+ 
2 Pool of random
units
420 100 O− 
3 Pool of random
units
360 100 O+ 
4 Apheresis 250 O+ 
5 Apheresis 250 O+ 
6 Apheresis 250 A+ 
7 Pool of random
units
300 100 O− 
8 Apheresis 250 O+ 
9 Apheresis 250 O+ 
10 Apheresis 250 O+ 
AH: absence of hemolysis.
a Eluate: anti-B.95 246
Discussion
The present study demonstrates that the results of IT, the gold-
standard prophylaxis against the hemolysis associated with
plasma-incompatible platelet transfusions, are not correlated
to the results of the QHT, the recently proposed prophylac-
tic strategy. Moreover in an exploratory analysis, the absence
of hemolysis in QHT did not prevent RBC sensitization after
transfusion and the implementation of this prophylaxis in the
blood bank routine negatively affected platelet inventory man-
agement due to a signiﬁcant increase in the number of units
classiﬁed as unsuitable for transfusion.
IT has been the method of choice for the prophylaxis
of hemolysis associated with plasma-incompatible platelet
transfusions in most blood bank services, mainly due to
reports of its safety in spite of the fact that the best cut-
off level remains elusive.5,6,11,12 The rationale underlying IT
prophylaxis is that incompatible transfused antibodies are
diluted within the recipients’ organism due to the pres-
ence of A and/or B antigens in epithelial tissues and in
plasmatic proteins, besides the RBC membrane. The higher
the titer of isohemagglutinins, the greater the chances of
RBC sensitization and passive hemolysis.13 Other alternatives
outcome after plasma-incompatible platelet transfusions.
Patient
QHT
result
ABO/
RhD
Signs  or
symptoms of
acute hemolysis
Post-
transfusional
DAT
Increase in
LDH/IB
AH B+ No Negative No
AH A− No Negative No
AH B+ No Negative No
AH AB+ No Negative No
AH B+ No Positive 3+a No
AH AB+ No Negative No
AH B+ No Negative No
AH A+ No Negative No
AH A+ No Negative No
AH A+ No Negative No
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o this strategy are platelet washing, which is associated
ith decreased transfusion efﬁcacy,1 or the preparation of
yper-concentrated platelets re-suspended in an additive
olution during storage, which is more  time-consuming and
xpensive.14
It is important to stress that group O blood donors typically
resent higher isohemagglutinin titers, a threat to recipients
n the case of incompatible platelet transfusions. Similarly,
pheresis platelet units with higher isohemagglutinin titers
re more  dangerous to incompatible recipients than random
latelet units, as their plasma content is higher and cannot
e diluted before transfusion. Thus, performing IT in type O
pheresis donors is a valid prophylactic strategy used by some
lood banks to avoid hemolytic reactions following plasma-
ncompatible platelet transfusions. One exception to this rule
s the use of random units for the transfusion of pediatric
atients, a situation associated with risk of hemolysis.
In our service, approximately 2468 transfusions of platelet
nits are performed each month and, of those, 5% have minor
BO incompatibilities. Since the implementation of IT as
emolysis prophylaxis ten years ago (cut-off level of 100),
o cases of acute hemolytic reactions have been reported.
onsidering a cut-off level of 128 (tube-method), 14.2% of our
ype O platelet units were considered as high-titer, irrespective
f the ABO typing. This data is consistent with other reports in
he literature, in which approximately 26.3% of type O platelet
nits exhibit isohemagglutinin titers greater than 256 (gel-
ethod).5,13 Since IT can be automatized, if a cut-off level of
00 is chosen, less than 15% of type O platelet units will be
onsidered ‘dangerous’ in most transfusion services, making
t easier to deal with shortages of platelets and avoiding the
xpiry of units.
QHT has recently been suggested as a possible substitute
o IT as the prophylaxis of choice for plasma-incompatible
latelet transfusions. There are two types of hemolysin test:
HT and the quantitative hemolysin test, which measures
he hemolysin titer and was not in the scope of this study.
HT evaluates whether the anti-A or anti-B antibodies are
apable, under the worst conditions, of causing RBC lysis. The
bjective of this test is different to that of IT, which evalu-
tes the titer of anti-A or anti-B antibodies capable of causing
BC agglutination. As demonstrated by our results, a higher
iter of isohemagglutinins does not foresee the presence of
emolysins within one sample, and vice versa.
Even though the rationale underlying this recently pro-
osed prophylactic method was valid (detecting the presence
f anti-A and anti-B antibodies capable of causing RBC lysis
n donor sera), it completely lacked evidence of efﬁcacy in the
iterature. The current study demonstrates that there is no cor-
elation between the results of IT and those of QHT. Hence,
ome platelet units with negative QHT results for hemolysis
suitable for transfusion) exhibited high IT and others low IT,
onsidering both the cut-offs of 128 and 64. As the safety of
HT had never been clinically evaluated, in contrast to that of
T, this proposal is a matter of concern.
The results of the exploratory analysis regarding the abilityf QHT to prevent RBC sensitization showed that 10% of recip-
ents who  received units with minor ABO incompatibilities
ith negative QHT results for hemolysis presented a posi-
ive DAT after transfusion. Even though the study sample was 1 5;3  7(4):217–222 221
small, due to ethical limitations, the percentage of RBC sen-
sitization was higher than that reported in the literature for
plasma-incompatible platelet transfusions (3.7%) with IT titers
greater than 512 (gel-method).13 As the object of prophylaxis in
plasma-incompatible platelet transfusions is to prevent acute
hemolysis, which is rare, a large cohort of patients transfused
based on QHT results alone is necessary to prove the clinical
efﬁcacy.
The implementation of QHT caused some logistic prob-
lems to the blood bank routine. It is known from the literature
that approximately 60% of isohemagglutinins are capable of
causing RBC lysis and, as a consequence, the percentage of
platelet units labeled as unsuitable for transfusion after the
implementation of this methodology in our service was sim-
ilar to other publications at 65%.15 This negatively affected
platelet inventory management and caused delays in the
transfusion process. Moreover, an extra blood sample had to
be collected from donors, due to the necessity of perform-
ing QHT using sera instead of plasma, which is the material
commonly available in the immunohematology laboratory. By
collecting this extra tube, the volume recommended by Brazil-
ian law regarding the maximum authorized blood volume that
can be collected for testing was exceeded.8 Finally, as the QHT
could not be automatized, it was performed manually by tech-
nicians, thereby increasing the chances of mistakes.
This study has some limitations. The most important
concerns the number of recipients transfused with non-
compatible platelet units based on QHT results, which was
low. Our main objective was to correlate QHT and IT results,
with the evaluation of RBC sensitization as secondary. The
ideal study design to evaluate the efﬁcacy of QHT in preven-
ting hemolytic reactions should involve at least 5000 patients.
However, considering the lack of correlation between QHT
and IT, the absence of studies in the literature addressing
the efﬁcacy of QHT in preventing hemolytic reactions, prob-
lems related to platelet inventory management using the QHT
routine and the proven efﬁcacy of IT in preventing hemolytic
complications, enrolling more  patients to be transfused based
only on QHT results would be against ethical principles.
Conclusions
QHT results do not correlate to IT and the implementa-
tion of this technique as the prophylaxis of choice against
the hemolysis associated with plasma-incompatible platelet
transfusions lacks clinical support of safety and would signif-
icantly affect platelet inventory management.
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